Clinical trials
Phase 3 HIV Infections trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
85 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2001 | 6 |
| 2002 | 3 |
| 2003 | 5 |
| 2004 | 3 |
| 2005 | 5 |
| 2006 | 2 |
| 2007 | 8 |
| 2008 | 6 |
| 2009 | 3 |
| 2010 | 7 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 4 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 73 |
| Terminated | 6 |
| Active, not recruiting | 5 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| ViiV Healthcare | 21 |
| French National Agency for Research on AIDS and Viral Hepatitis | 11 |
| Gilead Sciences | 9 |
| ANRS, Emerging Infectious Diseases | 8 |
| Boehringer Ingelheim | 5 |
| Bristol-Myers Squibb | 5 |
| Abbott | 4 |
| GlaxoSmithKline | 3 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| Tibotec Pharmaceuticals, Ireland | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| HIV Infections | 85 |
| Acquired Immunodeficiency Syndrome | 19 |
| Infections | 9 |
| HIV-Associated Lipodystrophy Syndrome | 3 |
| Hepatitis B | 2 |
| Cytomegalovirus Infections | 1 |
| Disease Progression | 1 |
| Dyslipidemias | 1 |
| HIV Seropositivity | 1 |
| Hepatitis A | 1 |
Trials
Showing 1 to 25 of 85. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.